Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC)

Virchows Archiv

Volumn 463, Issue 5, 2013, Pages 663-671

  Bellezza, Guido ^a,b   Del Sordo, Rachele ^a   Colella, Renato ^a   Ludovini, Vienna ^b   Ragusa, Mark ^a   Bianconi, Fortunato ^a   Ferri, Ivana ^a   Borri, Filippo ^a   Chiari, Rita ^b   Puma, Francesco ^a   Crinò, Lucio ^b   Sidoni, Angelo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

Co expression; HER family; Immunohistochemistry; Lung cancer; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; WEDGE RESECTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTOR PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84889102649     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-013-1445-x     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E et al (2008) Cancer statistics. CA Cancer J Clin 58:71-96
2. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359:1367-1380
3. Lynch TJ, Bonomi PD, Butts C et al (2007) Novel agents in the treatment of lung cancer: Fourth Cambridge Conference. Clin Cancer Res 13:s4583-s4588
4. Kumar A, Petri ET, Halmos B, Boggon TJ (2008) Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 26:1742-1751
5. Bazley LA, Gullick WJ (2005) The epidermal growth factor family. Endocr Relat Cancer 12(suppl. 1):S17-S27
6. Del Sordo R, Angiero F, Bellezza G et al (2010) HER family receptors expression in squamous cell carcinoma of the tongue: study of the possible prognostic and biological significance. J Oral Pathol Med 39:79-86
7. Barros FFT, Powe DG, Ellis IO, Green AR (2010) Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. Histopathology 56:560-572
8. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125:1137-1149
9. Hsieh AC, Moasser MM (2007) Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 97:453-457
10. Graus-Porta D, Beerli RR, Daly JM, Hynes NE (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16:1647-1655
11. Bromberg J (2002) Stat proteins and oncogenesis. J Clin Invest 109:1139-1142
12. Herbst RS, Shin DM (2002) Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94:1593-1611
13. Ludovini V, Bellezza G, Pistola L et al (2009) High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol 20:842-849
14. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139
15. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500
16. Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PA Jr (2002) HER2/neu expression in malignant lung tumors. Semin Oncol 29:51-58
17. Tsai CM, Chang KT, Wu LH et al (1996) Correlation between intrinsic chemoresistence and HER2/neu gene expression, p53 mutations and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res 56:206-209
18. Sithanandam G, Anderson LM (2008) The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther 15:413-448
19. Engelman JA, Cantley LC (2006) The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 12:4372-4376
20. Starr A, Greif J, Vexler A et al (2006) ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy. Int J Cancer 119:269-274
21. Wissner A, Monsour TS (2008) The development of HKI-272 and related compounds for the treatment of cancer. Arch Pharm (Weinheim) 341:465-477
22. Engelman JA, Zejnullahu K, Gale CM et al (2007) PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 67:11924-11932
23. Hirsch FR, Varella-Garcia M, Capuzzo F (2009) Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 28:s32-s37
24. Cagle PT, Chirieac LR (2012) Advances in treatment of lung cancer with target therapy. Arch Pathol Lab Med 136:504-509
25. Hilbe W, Dirnhofer S, Oberwasserlechner F et al (2003) Immunohistochemical typing of non-small cell lung cancer on cryostat sections: correlation with clinical parameters and prognosis. J Clin Pathol 56:736-741
26. Koutsopoulos AV, Mavroudis D, Dambaki KI et al (2007) Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: correlation with clinical outcome. Lung Cancer 57:193-200
27. Lai WW, Chen FF, Wu MH et al (2001) Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer. Ann Thorac Surg 72:1868-1876
28. Travis WD, Brambilla E, Müller-Hermelink KH, Curtis CH (2004) WHO classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC, Lyon
29. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC cancer staging manual. Springer, New York
30. Onn A, Correa AM, Gilcrease M et al (2004) Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 10:136-143
31. Reinmuth N, Brandt B, Kunze WP et al (2000) Ploidy, expression of erbB1, erbB2 and erbB3 in non-small cell lung cancer. Eur Respir J 16:991-996
32. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21:3798-3807
33. Meert AP, Martin B, Verdebout JM et al (2005) Is there a relationship between c-erbB-1 and c-erbB-2 amplification and protein overexpression in NSCLC? Lung Cancer 47:325-336
34. Xu S, Kitayama J, Yamashita H, Souma D, Nagawa H (2008) Nuclear translocation of HER-4/c-erbB-4 is significantly correlated with prognosis of esophageal squamous cell carcinoma. J Surg Oncol 97:44-50
35. Elenius K, Paul S, Allison G, Sun J, Klagsbrun M (1997) Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J 16:1268-1278
36. Tzahar E, Waterman H, Chen X et al (1996) A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16:5276-5287
37. Ono M, Hirata A, Kometani T et al (2004) Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 3:465-472
38. Amann J, Kalyankrishna S, Massion PP et al (2005) Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 65:226-235
39. Gilmore AP, Valentijn AJ, Wang P et al (2002) Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem 277:27643-27650
40. Morgillo F, Cantile F, Fasano M, Troiani T, Martinelli E, Ciardiello F (2009) Resistance mechanisms of tumour cells to EGFR inhibitors. Clin Transl Oncol 11:270-275
41. Doebele RC, Oton AB, Peled N, Camidge DR, Bunn PA Jr (2010) New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer 69:1-12
42. Gong HC, Wang S, Mayer G et al (2011) Signatures of drug sensitivity in non small cell lung cancer. Int J Proteomics. doi: 10.1155/2011/215496